The management of a patient with Duchenne muscular dystrophy regarding corticosteroid therapy has historically included the use of corticosteroids [ Moxley RT 3rd et al. 2005 ]. While specific current UK guidelines on corticosteroid therapy for Duchenne muscular dystrophy are not provided in the context, general principles for managing patients on oral corticosteroids are relevant NICE CKS. When a patient is prescribed long-term oral corticosteroids, it is important to be aware of potential side effects and the need for careful management NICE CKS. These can include a range of adverse effects, and the patient's care plan should address these NICE CKS. Furthermore, long-term corticosteroid use can lead to adrenal insufficiency, which requires careful identification and management NICE NG243. Patients on long-term corticosteroids should not stop treatment abruptly without medical advice due to the risk of adrenal crisis NICE CKS,NICE NG243. Regular monitoring and a clear management plan are essential for patients receiving corticosteroid therapy NICE CKS.
Key References
- CKS - Cushing's syndrome
- NG119 - Cerebral palsy in adults
- CKS - Croup
- CKS - Corticosteroids - oral
- NG42 - Motor neurone disease: assessment and management
- NG115 - Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NG243 - Adrenal insufficiency: identification and management
- (Moxley RT 3rd et al., 2005): Practice parameter: corticosteroid treatment of Duchenne dystrophy [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.